

BioXcel Therapeutics, Inc.
780 East Main Street
Branford, CT 06405

March 5, 2018

VIA EDGAR

United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes
Mary Beth Breslin
Ada D. Sarmento

Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-222990

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “**Act**”), BioXcel Therapeutics, Inc. (the “**Company**”) respectfully requests that the effective date of the registration statement referred to above (the “**Registration Statement**”) be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Wednesday, March 7, 2018, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Sheppard, Mullin, Richter & Hampton LLP by calling Stephen A. Cohen at (212) 653-8166. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Sheppard, Mullin, Richter & Hampton LLP, Attention: Stephen A. Cohen, by facsimile to (917) 438-6137.

If you have any questions regarding this request, please contact Stephen A. Cohen of Sheppard, Mullin, Richter & Hampton LLP at (212) 653-8166.

Very Truly Yours,

By: /s/ Vimal Mehta
Name: Vimal Mehta
Title: Chief Executive Officer

cc: Jeffrey J. Fessler, Sheppard Mullin, Richter & Hampton LLP
Stephen A. Cohen, Sheppard Mullin, Richter & Hampton LLP
